Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model

Biochemical and Biophysical Research Communications

Volumn 435, Issue 1, 2013, Pages 134-139

  Kwon, Sanghoon ^a   Kim, Young Eun ^b   Kim, Dongbum ^a   Park, Byoung Kwon ^a   Wu, Guang ^a   Kim, Te Ha ^a   Choi, Song Hee ^a   Kim, Doo Sik ^c   Kwon, Hyung Joo ^a   Lee, Younghee ^b  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Antibody; Colon cancer; DOPE:CHEMS; Lipoplex(O); Peptide vaccine; Prophylaxis; TM4SF5

Indexed keywords

CANCER VACCINE; PEPTIDE VACCINE; PROTEIN ANTIBODY; TM4SF5 ANTIBODY; TM4SF5 PEPTIDE CPG DNA LIPOSOME COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLON; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TIME FACTORS; TUMOR BURDEN;

MUS;

EID: 84878199024     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.057     Document Type: Article

References (29)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
2. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784-1787.
3. Khan N.P., Pandith A.A., Hussain M.U., Yousuf A., Khan M.S., Wani K.A., Mudassar S. Novelty of Axin 2 and lack of Axin 1 gene mutation in colorectal cancer: a study in Kashmiri population. Mol. Cell Biochem. 2011, 355:149-155.
4. Folsom A.R., Pankow J.S., Peacock J.M., Bielinski S.J., Heiss G., Boerwinkle E. Variation in TCF7L2 and increased risk of colon cancer: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008, 31:905-909.
5. Guo J., Cagatay T., Zhou G., Chan C.C., Blythe S., Suyama K., Zheng L., Pan K., Qian C., Hamelin R., Thibodeau S.N., Klein P.S., Wharton K.A., Liu W. Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS One 2009, 4:e7982.
6. Samowitz W.S., Holden J.A., Curtin K., Edwards S.L., Walker A.R., Lin H.A., Robertson M.A., Nichols M.F., Gruenthal K.M., Lynch B.J., Leppert M.F., Slattery M.L. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am. J. Pathol. 2001, 158:1517-1524.
7. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
8. Korchynskyi O., Landstrom M., Stoika R., Funa K., Heldin C.H., ten Dijke P., Souchelnytskyi S. Expression of Smad proteins in human colorectal cancer. Int. J. Cancer 1999, 82:197-202.
9. Forrester K., Almoguera C., Han K., Grizzle W.E., Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327:298-303.
10. Rychahou P.G., Jackson L.N., Silva S.R., Rajaraman S., Evers B.M. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann. Surg. 2006, 243:833-842. (discussion 843-834).
11. Richardson M.M., Jennings L.K., Zhang X.A. Tetraspanins and tumor progression. Clin. Exp. Metastasis 2011, 28:261-270.
12. Anderson K.R., Singer R.A., Balderes D.A., Hernandez-Lagunas L., Johnson C.W., Artinger K.B., Sussel L. The L6 domain tetraspanin Tm4sf4 regulates endocrine pancreas differentiation and directed cell migration. Development 2011, 138:3213-3224.
13. Lekishvili T., Fromm E., Mujoomdar M., Berditchevski F. The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility. J. Cell Sci. 2008, 121:685-694.
14. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 2009, 9:40-55.
15. Haeuw J.F., Goetsch L., Bailly C., Corvaia N. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem. Soc. Trans. 2011, 39:553-558.
16. Muller-Pillasch F., Wallrapp C., Lacher U., Friess H., Buchler M., Adler G., Gress T.M. Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 1998, 208:25-30.
17. Lee S.A., Lee S.Y., Cho I.H., Oh M.A., Kang E.S., Kim Y.B., Seo W.D., Choi S., Nam J.O., Tamamori-Adachi M., Kitajima S., Ye S.K., Kim S., Hwang Y.J., Kim I.S., Park K.H., Lee J.W. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J. Clin. Invest. 2008, 118:1354-1366.
18. Lee S.A., Kim Y.M., Kwak T.K., Kim H.J., Kim S., Ko W., Kim S.H., Park K.H., Cho M., Lee J.W. The extracellular loop 2 of TM4SF5 inhibits integrin alpha2 on hepatocytes under collagen type I environment. Carcinogenesis 2009, 30:1872-1879.
19. Lee S.A., Ryu H.W., Kim Y.M., Choi S., Lee M.J., Kwak T.K., Kim H.J., Cho M., Park K.H., Lee J.W. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 2009, 49:1316-1325.
20. Lee S.A., Park K.H., Lee J.W. Modulation of signaling between TM4SF5 and integrins in tumor microenvironment. Front Biosci. 2011, 16:1752-1758.
21. Kwon S., Kim D., Park B.K., Cho S., Kim K.D., Kim Y.E., Park C.S., Ahn H.J., Seo J.N., Choi K.C., Kim D.S., Lee Y., Kwon H.J. Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One 2012, 7:e33121.
22. Kwon S., Kim D., Park B.K., Wu G., Park M.C., Ha Y.W., Kwon H.J., Lee Y. Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol. Rep. 2013, 29:735-740.
23. Kim D., Rhee J.W., Kwon S., Kim Y.E., Choi S.Y., Park J., Lee Y., Kwon H.J. Enhancement of immunomodulatory activity by liposome-encapsulated natural phosphodiester bond CpG-DNA in a human B cell line. BMB Rep. 2010, 43:250-256.
24. Kim D., Kwon S., Rhee J.W., Kim K.D., Kim Y.E., Park C.S., Choi M.J., Suh J.G., Kim D.S., Lee Y., Kwon H.J. Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol. 2011, 12:29.
25. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Fukui H. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001, 7:1073-1078.
26. Bacolod M.D., Barany F. Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann. Surg. Oncol. 2011, 18:3694-3700.
27. Gallagher D.J., Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010, 78:237-248.
28. Kim D., Kwon H.J., Lee Y. Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep. 2011, 44:607-612.
29. Abbas A., Lichtman A., Pillai S. Cellular and Molecular Immunology 2007, Saunders, Elsevier, Philadelphia. sixth ed.